Rovunaptabin
Based on 1 Customer Validation
Rovunaptabin (ARC 183) is an aptamer, a single-stranded DNA molecule composed of 15 deoxynucleotides. It acts as a broad-spectrum neutralizer of pathogenic G-protein-coupled receptor autoantibodies. Rovunaptabin can be used in research related to cardiomyopathy and pulmonary hypertension.
For research use only. We do not sell to patients.
- Purity : 99.49%
- CAS No.: 145563-68-4
- Molecular Weight:4726.07
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Rovunaptabin (100 nM; 1 h) shows species-specific neutralization in spontaneously beating neonatal rat cardiomyocytes, fully neutralizing rat and rabbit G-protein-coupled receptor autoantibodies, partially neutralizing goat autoantibodies, and failing to neutralize chicken autoantibodies[1].
Rovunaptabin (100 nM) binds to the Fab region of human ETA-receptor and beta1-adrenoceptor autoantibodies, preventing restoration of agonistic activity via cross-linking in spontaneously beating neonatal rat cardiomyocytes[1].
Rovunaptabin (1 μM) forms a detectable complex with 1.5 μM human beta1-adrenoceptor autoantibodies in an electrophoretic mobility shift assay[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Treatment with Rovunaptabin (BC 007) (1-4 mg/kg; i.v. infusion over 20 min; single dose; second single dose (9 months after initial)) safely neutralizes β1-adrenergic receptor autoantibodies in β1-AAB-positive Doberman Pinschers with dilated cardiomyopathy, reduces or stabilizes left ventricular volumes during β1-AAB-free periods, and significantly prolongs median cardiac survival to 572 days[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:purebred Doberman Pinschers[2]
-
Dosage:1-4 mg/kg; 1 mg/kg
-
Administration:i.v. infusion over 20 min; single dose;
-
Result:Neutralized β1-adrenergic receptor autoantibodies in β1-AAB-positive Doberman Pinschers with dilated cardiomyopathy. Reduced or stabilized left ventricular volumes during β1-AAB-free periods, and significantly prolonged median cardiac survival to 572 days.
Chemical Information
-
CAS No. 145563-68-4
-
Appearance Solid
-
Molecular Weight 4726.07
-
Color White to off-white
-
SMILES
DNA, d(G-G-T-T-G-G-T-G-T-G-G-T-T-G-G)
-
Synonyms
ARC 183; BC 007
-
Sequence
DNA, d(G-G-T-T-G-G-T-G-T-G-G-T-T-G-G)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
-
Data Sheet (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (1518 KB)
References
[1]. Haberland A, et al. Aptamer BC 007 - A broad spectrum neutralizer of pathogenic autoantibodies against G-protein-coupled receptors. Eur J Pharmacol. 2016;789:37-45. [Content Brief]
[2]. Werner S, et al. The aptamer BC 007 for treatment of dilated cardiomyopathy: evaluation in Doberman Pinschers of efficacy and outcomes. ESC Heart Fail. 2020;7(3):844-855. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rovunaptabin Related Classifications
HY-148826 Related Classifications
Powered by Bioz
Keywords
- Rovunaptabin
- 145563-68-4
- ARC 183
- BC 007
- ARC183
- ARC-183
- BC007
- BC 007
- BC-007
- G Protein-coupled Receptor Kinase (GRK)
- ET?-receptor
- neonatal rat cardiomyocytes
- Doberman Pinschers
- M2-muscarinic receptor
- β1-adrenoceptor
- α1-adrenoceptor
- β2-adrenoceptor
- G-protein-coupled receptor autoantibodies
- AT1-receptor
- proteinase activated receptor
- Inhibitor
- inhibitor
- inhibit